TNF and inflammatory bowel disease: Over the last 2 decades, biological TNF inhibitors, such as ADA, have led to achievable outcomes in patients with a wide variety of immune-mediated inflammatory diseases, including rheumatoid arthritis, axial spondyloarthropathy, and IBD.